Skip to main content
. Author manuscript; available in PMC: 2015 Mar 13.
Published in final edited form as: JAMA Intern Med. 2015 Mar 1;175(3):401–407. doi: 10.1001/jamainternmed.2014.7663

Table 2.

Any and Cumulative Anticholinergic Use During Study Period

All participants (N=3434) TSDD a
Medication Class Nb % Total TSDD filled % of all TSDD
Antihistamines 2,224 64.8 1,158,404 17.2
Gastrointestinal antispasmodics 1,566 45.6 365,141 5.4
Antivertigo/antiemetics 1,433 41.7 154,488 2.3
Antidepressants 1,352 39.4 4,241,590 63.1
Bladder antimuscarinics 668 19.5 702,825 10.5
Skeletal muscle relaxants 175 5.1 20,274 0.3
Antipsychotics 38 1.1 45,888 0.7
Antiarrhythmic 22 0.6 31,249 0.5
Antiparkinson agents 12 0.3 1,615 0.0
Total 6,721,473 100.0

TSDD Total Standardized Daily Dose

a

A participant’s study period included 10 years prior to study entry through the time they were diagnosed with dementia or censored. We summed TSDD for all participants for their entire study period.

b

Number of participants with at least 1 fill for a medication in the category at any time during the follow-up period. Participants may have fills in multiple drug categories so the percentages do not sum to 100%.